Nectar Lifesciences Ltd.

As of June 30, 2026, Nectar Lifesciences Ltd. carries a market capitalization of 2.26B, placing it among publicly traded companies globally. Its enterprise value stands at 2.26B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Nectar Lifesciences Ltd. has 194.26M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Nectar Lifesciences Ltd. trades at an EV/EBITDA multiple of 162.72 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 45.16 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 242.98 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 2.26B versus a market cap of 2.26B, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 52,831.84 in revenue per employee across its workforce of 948.50, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Nectar Lifesciences Ltd. recorded an income tax benefit of -398.19M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -254.53M and -693.81M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 23, 2026, Nectar Lifesciences Ltd.'s stock has declined approximately 24.10% over the past 52 weeks. The 50-day moving average sits at 11.14, while the 200-day moving average is 12.08.

Over the twelve months ended June 30, 2026, Nectar Lifesciences Ltd. generated 50.11M in revenue and converted that into -693.81M in net income, yielding earnings per share of 0.68. EBITDA reached 13.91M, while operating income came in at -872.20M.

Over the twelve months ended June 30, 2026, Nectar Lifesciences Ltd. posted a gross margin of 32.79, reflecting its pricing power and cost economics. The operating margin of -1,740.53 and net profit margin of -1,384.56 provide insight into operational efficiency.

Nectar Lifesciences Ltd.'s most recent stock split took place on November 12, 2008 with a 1:10 split ratio.